UCB SA (UCB.BR)
EUR 187.45
(0.83%)
EUR 187.45
(0.83%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.03 Billion EUR | 4.76% |
| 2022 | 2.9 Billion EUR | 36.6% |
| 2021 | 2.12 Billion EUR | -22.72% |
| 2020 | 2.74 Billion EUR | 114.44% |
| 2019 | 1.28 Billion EUR | -14.54% |
| 2018 | 1.49 Billion EUR | -4.7% |
| 2017 | 1.57 Billion EUR | -1.75% |
| 2016 | 1.6 Billion EUR | -36.04% |
| 2015 | 2.5 Billion EUR | 18.07% |
| 2014 | 2.12 Billion EUR | -22.91% |
| 2013 | 2.75 Billion EUR | 31.77% |
| 2012 | 2.08 Billion EUR | 14.86% |
| 2011 | 1.81 Billion EUR | -12.05% |
| 2010 | 2.06 Billion EUR | -7.89% |
| 2009 | 2.24 Billion EUR | -23.0% |
| 2008 | 2.91 Billion EUR | 20.37% |
| 2007 | 2.42 Billion EUR | -22.29% |
| 2006 | 3.11 Billion EUR | 195.17% |
| 2005 | 1.05 Billion EUR | -52.43% |
| 2004 | 2.21 Billion EUR | 446.05% |
| 2003 | 406.13 Million EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.84 Billion EUR | 0.0% |
| 2023 FY | 3.03 Billion EUR | 4.76% |
| 2023 Q2 | 2.89 Billion EUR | 0.0% |
| 2023 Q4 | 3.03 Billion EUR | 0.0% |
| 2022 FY | 2.9 Billion EUR | 36.6% |
| 2022 Q2 | 3.01 Billion EUR | 0.0% |
| 2022 Q4 | 2.9 Billion EUR | 0.0% |
| 2021 Q2 | 2.08 Billion EUR | 0.0% |
| 2021 Q4 | 2.12 Billion EUR | 0.0% |
| 2021 FY | 2.12 Billion EUR | -22.72% |
| 2020 Q4 | 2.74 Billion EUR | 0.0% |
| 2020 Q2 | 2.88 Billion EUR | 0.0% |
| 2020 FY | 2.74 Billion EUR | 114.44% |
| 2019 Q4 | 1.28 Billion EUR | 0.0% |
| 2019 FY | 1.28 Billion EUR | -14.54% |
| 2019 Q2 | 1.38 Billion EUR | 0.0% |
| 2018 Q4 | 1.49 Billion EUR | 0.0% |
| 2018 FY | 1.49 Billion EUR | -4.7% |
| 2018 Q2 | 1.66 Billion EUR | 0.0% |
| 2017 FY | 1.57 Billion EUR | -1.75% |
| 2017 Q2 | 1.57 Billion EUR | 0.0% |
| 2017 Q4 | 1.57 Billion EUR | 0.0% |
| 2016 Q4 | 1.6 Billion EUR | 0.0% |
| 2016 FY | 1.6 Billion EUR | -36.04% |
| 2016 Q2 | 2.16 Billion EUR | 0.0% |
| 2015 Q4 | 2.2 Billion EUR | 0.0% |
| 2015 Q2 | 2.33 Billion EUR | 0.0% |
| 2015 FY | 2.5 Billion EUR | 18.07% |
| 2014 Q2 | 2.36 Billion EUR | 0.0% |
| 2014 FY | 2.12 Billion EUR | -22.91% |
| 2014 Q4 | 2.12 Billion EUR | 0.0% |
| 2013 Q4 | 2.75 Billion EUR | 0.0% |
| 2013 FY | 2.75 Billion EUR | 31.77% |
| 2013 Q2 | 2.46 Billion EUR | 0.0% |
| 2012 Q2 | 2.07 Billion EUR | 0.0% |
| 2012 FY | 2.08 Billion EUR | 14.86% |
| 2012 Q4 | 2.08 Billion EUR | 0.0% |
| 2011 Q4 | 1.81 Billion EUR | 0.0% |
| 2011 Q2 | 1.76 Billion EUR | 0.0% |
| 2011 FY | 1.81 Billion EUR | -12.05% |
| 2010 FY | 2.06 Billion EUR | -7.89% |
| 2010 Q4 | 2.06 Billion EUR | 0.0% |
| 2010 Q2 | 2.76 Billion EUR | 0.0% |
| 2009 Q4 | 2.24 Billion EUR | 0.0% |
| 2009 FY | 2.24 Billion EUR | -23.0% |
| 2008 FY | 2.91 Billion EUR | 20.37% |
| 2007 FY | 2.42 Billion EUR | -22.29% |
| 2006 FY | 3.11 Billion EUR | 195.17% |
| 2005 FY | 1.05 Billion EUR | -52.43% |
| 2004 FY | 2.21 Billion EUR | 446.05% |
| 2003 FY | 406.13 Million EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -89516.519% |
| ABIVAX Société Anonyme | 55.46 Million EUR | -5377.427% |
| Adocia SA | 13.08 Million EUR | -23112.103% |
| Aelis Farma SA | 4.03 Million EUR | -75135.265% |
| Biophytis S.A. | 8.27 Million EUR | -36635.187% |
| Advicenne S.A. | 17.42 Million EUR | -17334.72% |
| genOway Société anonyme | 7.23 Million EUR | -41899.595% |
| IntegraGen SA | 1.12 Million EUR | -270008.07% |
| Medesis Pharma S.A. | 1.2 Million EUR | -253066.667% |
| Neovacs S.A. | 650 Thousand EUR | -467284.615% |
| NFL Biosciences SA | 62.17 Thousand EUR | -4886186.872% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -69634.735% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -111721.127% |
| Sensorion SA | 2.86 Million EUR | -105798.416% |
| Theranexus Société Anonyme | 3.64 Million EUR | -83292.327% |
| TME Pharma N.V. | 1.16 Million EUR | -260448.885% |
| Valbiotis SA | 6.87 Million EUR | -44069.817% |
| TheraVet SA | 1.15 Million EUR | -261826.583% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -33663.058% |
| argenx SE | 18.1 Million EUR | -16679.634% |
| BioSenic S.A. | 28.16 Million EUR | -10687.969% |
| Celyad Oncology SA | 902 Thousand EUR | -336707.095% |
| DBV Technologies S.A. | 13.01 Million USD | -23235.837% |
| Galapagos NV | 9.59 Million EUR | -31559.025% |
| Genfit S.A. | 70.17 Million EUR | -4228.992% |
| GeNeuro SA | 7.73 Million EUR | -39161.806% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -57285.72% |
| Innate Pharma S.A. | 39.89 Million EUR | -7515.371% |
| Inventiva S.A. | 37.4 Million EUR | -8021.475% |
| MaaT Pharma SA | 14.07 Million EUR | -21484.369% |
| MedinCell S.A. | 58.96 Million EUR | -5052.558% |
| Nanobiotix S.A. | 50.56 Million EUR | -5908.108% |
| Onward Medical N.V. | 16.87 Million EUR | -17904.03% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -22095.846% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | -6533.043% |
| Oxurion NV | 12.33 Million EUR | -24531.101% |
| Pharming Group N.V. | 155.29 Million EUR | -1856.295% |
| Poxel S.A. | 46.9 Million EUR | -6377.612% |
| GenSight Biologics S.A. | 18.42 Million EUR | -16385.783% |
| Transgene SA | 1.25 Million EUR | -241586.555% |
| Financière de Tubize SA | 79.2 Million EUR | -3735.859% |
| Valneva SE | 208.81 Million EUR | -1354.869% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -7994636.842% |